Estats Units - anglès - NLM (National Library of Medicine)

rebel distributors corp - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - griseofulvin 125 mg in 5 ml - major indications for griseofulvin oral suspension are: griseofulvin inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as: note: prior to therapy, the type of fungi responsible for the infection should be identified. the use of the drug is not justified in minor or trivial infections which will respond to topical antifungal agents alone. it is not effective in: this drug is contraindicated in patients with porphyria, hepatocellular failure, and in individuals with a history of hypersensitivity to griseofulvin. two cases of conjoined twins have been reported in patients taking griseofulvin during the first trimester of pregnancy. griseofulvin should not be prescribed to pregnant patients.

Estats Units - anglès - NLM (National Library of Medicine)

sigmapharm laboratories, llc - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - griseofulvin is indicated for the treatment of dermatophyte infections of the skin not adequately treated by topical therapy, hair and nails, namely: tinea corporis tinea pedis tinea cruris tinea barbae tinea capitis tinea unguium when caused by one or more of the following species of fungi: epidermophyton floccosum microsporum audouinii microsporum canis microsporum gypseum trichophyton crateriform trichophyton gallinae trichophyton interdigitalis trichophyton megnini trichophyton mentagrophytes trichophyton rubrum trichophyton schoenleini trichophyton sulphureum trichophyton tonsurans trichophyton verrucosum note: prior to therapy, a dermatophyte should be identified as responsible for the infection. prior to initiating treatment, appropriate specimens for laboratory testing (koh preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis. griseofulvin is not effective in the following: bacterial infections candidiasis (moniliasis) histoplasmosis actinomycosis spo

Estats Units - anglès - NLM (National Library of Medicine)

bimeda, inc. - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - indications equine - ringworm infection caused by trichophyton equinum and microsporum gypseum . adults - 1 packet per day (2.5 grams). yearlings - 1/2 to 1 packet per day (1.25-2.5 grams). foals - 1/2 packet per day. cases of ringworm in horses caused by t. equinum and m. gypseum should be treated with the griseofulvin powder (microsize) product for a period of not less than 10 days. responsive cases may show clinical signs of recovery in 5 to 7 days after griseofulvin therapy is initiated. in responsive cases, treatment should be continued until all infected areas are negative by appropriate culture. if cases do not respond to therapy in 3 weeks, it is recommended that the diagnosis be reevaluated. the powder may be given on a small amount of feed or in a drench.

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - griseofulvin -

Estats Units - anglès - NLM (National Library of Medicine)

heritage pharmaceuticals inc d/b/a avet pharmaceuticals inc - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - griseofulvin is contraindicated in patients with porphyria or hepatocellular failure, and in individuals with a history of hypersensitivity to griseofulvin. griseofulvin may cause fetal harm when administered to a pregnant woman. two published cases of conjoined twins have been reported in patients taking griseofulvin during the first trimester of pregnancy, therefore, griseofulvin is contraindicated in women who are or may become pregnant during treatment. women taking estrogen-containing oral contraceptives may be at increased risk of becoming pregnant while on griseofulvin (see also precautions, drug interactions ) . if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. although no direct causal relationship has been established, spontaneous abortion has been reported rarely coincident with the use of griseofulvin. note: the maximum recommend human dose (mrhd) was set at 500 mg/day for the multi

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

essential generics ltd - griseofulvin - oral tablet - 500mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - griseofulvin - oral tablet - 500mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - griseofulvin - oral tablet - 500mg

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

brown & burk ir limited - griseofulvin - film-coated tablet - 500 milligram(s) - antifungals for systemic use; griseofulvin

Estats Units - anglès - NLM (National Library of Medicine)

chartwell rx, llc. - griseofulvin (unii: 32hrv3e3d5) (griseofulvin - unii:32hrv3e3d5) - ultramicrosize griseofulvin tablets are indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete’s foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber’s itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: trichophyton rubrum , trichophyton tonsurans, trichophyton mentagrophytes, trichophyton interdigitalis,trichophyton verrucosum, trichophyton megnini, trichophyton gallinae, trichophyton crateriform, trichophyton sulphureum, trichophyton schoenleini, microsporum audouini, microsporum canis, microsporum gypseum and epidermophyton floccosum. note: prior to therapy, the type of fungi responsible for the infection should be identified. the use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. griseofulvin is